Advanced Practice

Peptide Receptor Radionuclide Therapy: An Emerging Treatment for Gastrointestinal Neuroendocrine Tumors

Adria Myers

Holly Chitwood

peptide receptor radionuclide therapy (PRRT), neuroendocrine, carcinoid syndrome
CJON 2020, 24(2), 129-133. DOI: 10.1188/20.CJON.129-133

Neuroendocrine tumors (NETs) are comprised of biologically diverse neoplasms. The presence of systemic symptoms is dependent on NET location and differentiation. New treatment modalities have become available, offering patients improved symptom management and survival. Advanced practice RNs (APRNs) provide direct care to and coordination of treatment for patients with NETs, including treatment of somatostatin receptor–positive disease with lutetium Lu 177 dotatate (Lutathera®) peptide receptor radionuclide therapy.


  • NETs are complex and may cause a variety of symptoms, such as those associated with carcinoid syndrome. 
  • APRNs are key members of the interprofessional team and are involved in the diagnosis, treatment, and coordination of care of patients with NETs. 
  • Somatostatin receptor–positive NETs may be treated with targeted treatments containing radioactive isotopes, such as lutetium Lu 177 dotatate.
Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.